Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, announced today that Pfizer's blockbuster drug Viagra will face major competition from new oral phosphodiesterase inhibitors such as tadalafil (Eli Lilly/ICOS's Cialis) and vardenafil (Bayer/GlaxoSmithKline's Nuviva). The report entitled Erectile Dysfunction finds that new therapies will drive sales in the seven major pharmaceutical markets (United States, France, Germany, Spain, Italy, United Kingdom, and Japan) to $2.6 billion in 2006 and $3.6 billion in 2011.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"There are two major drivers for the erectile dysfunction market; first, new erectile dysfunction therapies are expected to produce faster onset of action, longer duration of action and fewer side effects," said Kat Neumeyer, analyst at Decision Resources. "These improved therapies will provide the second market driver-an increasing drug-treated population-by giving patients more alternatives when first-line oral agents are ineffective."

Viagra's Dominance

The 1998 market debut of Pfizer's Viagra (sildenafil) revolutionized the management of erectile dysfunction and quickly established Viagra as a blockbuster drug. In 2001, the erectile dysfunction market in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) continued to be dominated by Viagra, which claimed 93% of the $1.3 billion major-market sales.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Diseases, Onkos, Metabolic, and Psychiatric Disorders concentrate on specific therapeutic areas. Mosaic covers high- interest disease states. Erectile Dysfunction is a Mosaic report.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563    emarshall@dresources.com 

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X87689256

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563, or
emarshall@dresources.com

Minimal Opportunity Remains for Vanlev Post FDA Rejection

View Now